Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Scientific Advisory Board

Elizabeth P. Rakoczy, PhD
Chair

Dr. Rakoczy is the Winthrop Professor of Molecular Ophthalmology at the Lions Eye Institute, University of Western Australia, and has pioneered work in gene therapy for ocular neovascular disease.


Jean E. Bennett, MD, PhD

Dr. Bennett is the F.M. Kirby Professor of Ophthalmology at the University of Pennsylvania and is a renowned expert in gene therapy, animal models, and translational medicine in retinal disease.


Estuardo Aguilar-Cordova, MD, PhD

Dr. Aguilar-Cordova is the Chief Executive Officer, Advantagene, and a recognized expert in regulatory affairs and product development in both academic and biotechnology settings.


Mitchell H. Finer, PhD

Dr. Finer is the Chief Scientific Officer of bluebird bio and has over 25 years of experience in biotechnology product development.


Daniel V. Palanker, PhD

Dr. Palanker is the Associate Professor in the Department of Ophthalmology and in Hansen Experimental Physics Laboratory at Stanford University. He is an expert in ophthalmic lasers and in interactions of pulsed electric field and light with biological cells and tissues.

Avalanche Biotechnologies to Participate in Nomura's Biotechnology Conference

October 30, 2014

MENLO PARK, CA – October 30, 2014 – Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Linda C. Bain, Chief Financial Officer, will participate in the "From Successful IPOs to Clinical Success: A Focus on New Crop of Companies Focused on Disorders of the Eye," panel discussion at Nomura's Biotechnology Conference on Thursday, November 6, 2014 at 10:00 am EST in Boston, MA.

Read More

Read All Avalanche News